Tag Archives: rebound

Goldman Sachs thinks the surprisingly lackluster April jobs report could be partially explained on the generosity of Uncle Sam.  “We see two partial explanations for the payrolls disappointment. First, reopening effects likely overlapped with normal seasonal hiring patterns, resulting in less-impressive job gains on a seasonally-adjusted basis. Second, labor supply appears to be tighter than the unemployment rate suggests, likely reflecting the impact of unusually generous unemployment… Source link

undefined Stock traded higher on Monday as technology stocks rose to recover some of last week’s declines. [Click here to read what’s moving markets heading into Tuesday, March 23] The Dow turned positive even as shares of component companies JPMorgan Chase (JPM) and Goldman Sachs (GS) lagged. Bank stocks, industrials and other cyclical shares including small caps underperformed, giving back some recent gains. Technology shares outperformed after another week of declines last week, and the… Source link

TipRanks Raymond James: These 3 Stocks Are Poised to Surge by at Least 50% In a recent note on the state of the stock markets, Raymond James equity strategist Tavis McCourt points out a series of policy factors that are playing a role in the current market volatility; the situation is more complex, perhaps, than most of us have been willing to admit. McCourt notes permutations of the SLR rule, political dynamics on the Senate Banking Committee, and the regulatory atmosphere towards potential… Source link

TipRanks Billionaire Steven Cohen Picks Up These 3 “Strong Buy” Stocks Last week, the NASDAQ slipped below 13,200, making the net loss from its all-time peak, reached earlier this month, 6.4%. If this trend keeps up, the index will slip into correction territory, a loss of 10% from its peak. So what exactly is going on? At bottom, it’s mixed signals. The COVID-19 pandemic is starting to fade and the economy is starting to reopen – strong positives that should boost markets. But an… Source link

TipRanks The Bottom Is in for These 2 Stocks? Analysts Say ‘Buy’ Today, we’re looking at two small-cap biotech firms whose stocks have struck a rut. Each company has hit a recent clinical setback that sent the share price falling, erasing previous gains and sending it back down to low levels. Setbacks of this sort are not uncommon in the biotech industry, and in fact highlight the risk and speculative nature of the industry. So what should investors do, when a stock collapses? Is this a… Source link